Researchers at the University of Cambridge have completed the first-ever human clinical trial of a vaccine component designed entirely by artificial intelligence. The Phase 1 trial, involving 39 healthy volunteers, demonstrated that the AI-crafted antigen was safe and capable of generating immune responses against not just SARS-CoV-2, but also SARS and bat-borne coronaviruses that haven’t yet jumped to humans.
How an algorithm built a better antigen
The project was led by Prof. Jonathan Heeney of the Cambridge Lab of Viral Zoonotics and DIOSynVax (DVX) Ltd, a spinout company focused on computationally designed vaccines. Their AI system ingests genetic sequence data from global coronavirus surveillance, essentially reading the molecular blueprints of every known Sarbecovirus strain circulating in animals and humans.
From that data, the machine learning model identifies conserved features, the structural elements that remain stable across different strains even as viruses mutate. Instead of targeting the parts of a virus that change rapidly, the AI zeroes in on the parts that stay the same.
The output is what the team calls a “super-antigen,” a single synthetic protein designed to train the immune system to recognize a broad family of coronaviruses rather than just one specific variant.
